Results of phase 3 PADRES trial of neoadjuvant axitinib in renal cell carcinoma

Lead author Kevin Hakimi discusses the background and results of the study, “Interim analysis of PADRES (prior axitinib as a determinant of outcome of renal surgery NCT03438708) clinical trial,” which he presented at the 2022 AUA Annual Meeting (LBA01-08).

Related Videos
Madison Novosel, BA, in an interview with Urology Times
Veda Giri, MD, answers a question during a Zoom video interview
Dr. Bertrand F. Tombal in an interview with Urology Times
Related Content
© 2023 MJH Life Sciences

All rights reserved.